SciSparc Ltd. a specialty clinical-stage pharmaceutical company based in Tel Aviv, Israel, has recently made a significant announcement regarding its plans for future growth and development. In a press release, the company revealed that it has entered into a standby equity purchase agreement (SEPA) with YA II PN, Ltd. a fund managed by Yorkville Advisors Global, LP. This agreement will enable SciSparc to secure up to $20 million in funds over the next thirty-six months, facilitating the expansion of their innovative therapies aimed at treating disorders and rare diseases of the central nervous system.
Advancing Clinical Research and Development:SciSparc’s primary focus is on the development of therapies for central nervous system disorders, which have long been underserved by the pharmaceutical industry. With the financial support from YA, the company will be able to advance their clinical research and development efforts, bringing them closer to providing effective treatments for patients suffering from these debilitating conditions. The funds will be crucial in accelerating the timeline for clinical trials and potential regulatory approvals.
Terms of the Standby Equity Purchase Agreement:Under the SEPA, YA has committed to purchasing up to $20 million of SciSparc’s ordinary shares over the next three years. However, the agreement includes a beneficial ownership cap of 4.99% of the share capital of the company. This precautionary measure prevents YA from exerting undue influence on the decision-making process or control of the company.
Pricing Determination:The purchase price of the ordinary shares will be at a 3% discount based on the weighted average price of SciSparc’s ordinary shares during the three consecutive trading days following the delivery of an advance notice by the company. This arrangement provides an opportunity for both parties to benefit from potential market fluctuations, ensuring a fair and mutually advantageous agreement.
Further Expansion Prospects:The press release also alludes to SciSparc’s intentions to explore additional avenues for expansion and increasing revenues. The company has indicated its interest in transferring its pharmaceutical activities to a separate legal entity, which could streamline operations and promote further growth. Additionally, they have expressed a commitment to evaluate the possibility of dividend distribution, which could be a significant development for shareholders.
Implications of the Non-Binding Letter of Intent:In a related statement, SciSparc revealed that they have signed a non-binding letter of intent to merge with a leading vehicle importer company in Israel. While the details of this potential merger are yet to be finalized, it demonstrates the company’s strategic vision and its desire to explore new opportunities. This partnership could result in valuable synergies and enhanced market presence for SciSparc, potentially boosting their research capabilities and expanding their reach.
Conclusion:The recent announcement of the standby equity purchase agreement with YA II PN, Ltd. marks a significant milestone for SciSparc Ltd. With access to $20 million in funds, the company is well-positioned to continue developing innovative therapies for central nervous system disorders. Furthermore, their plans to explore transferring pharmaceutical activities to a separate entity, along with the possibility of dividend distribution and a potential merger, illustrate SciSparc’s determination to scale up revenues and maximize opportunities for growth. As the company pushes forward with these strategic initiatives, stakeholders and investors can expect a compelling future for SciSparc in the pharmaceutical industry.
Comments